IGC Pharma (IGC) Equity Average (2011 - 2026)

IGC Pharma (IGC) has 16 years of Equity Average data on file, last reported at $6.8 million in Q1 2026.

• Equity Average for Q1 2026 came in at $6.8 million, up 7.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.8 million (up 7.59% YoY), and the FY2026 annual result was $6.2 million, down 8.79% from the prior year.
• Equity Average slipped to $6.8 million in Q1 2026 per IGC's latest filing, from $7.8 million in the prior quarter.
• Over five years, Equity Average peaked at $26.7 million in Q1 2022 and troughed at $6.2 million in Q2 2025.
• A 5-year average of $12.4 million and a median of $8.2 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average sank 50.72% in 2024, then grew 13.78% in 2025.
• A 5-year view of Equity Average shows it stood at $19.2 million in 2022, then sank by 39.81% to $11.6 million in 2023, then plunged by 41.1% to $6.8 million in 2024, then grew by 13.78% to $7.8 million in 2025, then retreated by 12.7% to $6.8 million in 2026.
• Business Quant data shows IGC's Equity Average at $6.8 million in Q1 2026, $7.8 million in Q4 2025, and $7.1 million in Q3 2025.